When a medicinal product is the subject of a reassessment of the risk-benefit balance, the Director General of the Agence nationale de sécurité du médicament et des produits de santé shall inform the manufacturer without delay. He shall also inform the operator without delay of the completion and outcome of the reassessment.
If the reassessment results in a change to the marketing authorisation or registration requiring a change to the information contained in an advertisement which, prior to the reassessment, was endorsed in accordance with articles L. 5122-8 or L. 5122-9, the operator must obtain a new endorsement in order to resume advertising. In this case, notwithstanding the provisions of articles R. 5122-5 and R. 5122-13, the application for approval may be submitted outside the periods determined by decision of the Director General of the Agency and is deemed to have been accepted in the absence of a decision by the Director General within two months of the date of receipt of the application.